Abbreviations:
thrombocytopenia, chronic liver disease
THROMBOCYTOPENIA, MITCHELL, CHRONIC LIVER DISEASE
adverse eventsconfidence intervalchronic liver diseaseChild–Turcotte–Pughelectronic case report formfood and drug administrationgastrointestinalstandard deviationtreatment-emergent AEsthrombopoietin receptor agonistThe datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.Supplemental Digital Content is available for this article.Brian Jamieson is an employee of Sobi, Inc. and was an employee of Dova Pharmaceuticals, a Sobi company. Mitchell L. Shiffman has received fees for participating in advisor meetings with AbbVie, Exelexis, Gilead, HepQuagnt, Intercept and Intra-Sana and discloses grant support from Celgene, CymaBay, Durect, Enanta, Galectin, Genfit, Gilead, HepQuant, Hamni, High Tide, Intercept, Madrigal, Mirum, Novo Nordisk, Pliant, and Viking. Mitchell L. Shiffman has also received speaker fees from AbbVie, Gilead, Genentech, Intercept, Intra-Sana, Mallinkrodt. Sanjaya K. Satapathy has served as a speaker for Intercept, Alexion, Dova, as an advisory board member for Gilead, Intercept, Bayer and has received research funding from Novartis, Fibronostics Gilead, Biotest, Genfit, Conatus, Intercept, Shire, Exact Sciences, Eananta, Dova, Bayer. Sanjaya K. Satapathy is an employee of Northwell Health. The study was funded by Dova Pharmaceuticals, a Sobi company. Medical writing and editorial support, funded by Sobi, was provided by Catherine Hoare, PhD, Bioscript Group, Macclesfield, UK.The authors have no conflicts of interest to disclose.How to cite this article: Satapathy SK, Sundaram V, Shiffman ML, Jamieson BD. Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure. Medicine 2023;102:40(e35208).